Back to Authors

Segal, Neil Howard

0000-0002-3047-2303

A5062202820 | I1334819555

Mayo Clinic

Memorial Sloan Kettering Cancer Center

Citations 2

Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4502-4502

10.1200/jco.2016.34.15_suppl.4502

Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8517-8517

10.1200/jco.2018.36.15_suppl.8517